Vanishing Bone Disease Market Scenario:
The Global Vanishing Bone Disease Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global vanishing bone disease market is expected to register a CAGR ~6.1 % during the forecast period of 2018–2023.
According to the National Center for Advancing Translational Sciences (NIH), in 2016, the number of cases of vanishing bone disease reported ranged from 64 to 200 cases globally. The growing occurrence of the disease is the key driver for the growth of the market. Furthermore, current research for the development of the effective therapeutic intervention for the disease treatment is expected to contribute to the growth of the market.
Vanishing bone disease or Gorham-stout syndrome is a rare skeletal disease characterized by progressive osteolysis and the proliferation of lymphatic vessels within the bone which leads to the destruction and absorption of bone. Additionally, the bones affected by the disease are more prone to osteopenia and fracture. Furthermore, the exact cause of the disease is unknown. However, it is considered to be caused due to the improper development of the lymphatic system.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/6147
Global Vanishing Bone Disease Market Segmentation
The Global Vanishing Bone Disease Market is segmented on the basis of the diagnosis, treatment, and end-user. On the basis of diagnosis, the market is classified as X-rays, CT scans, MRIs, ultrasound, nuclear medicine, and others.
The global vanishing bone disease market on the basis of treatment is segmented as medical therapy and radiation therapy. The medicine therapy is segmented into bisphosphonates, vitamin D, interferon, a-2b interferon, calcium, adrenal extracts, androgen, bleomycin, and others. The radiation therapy is further segmented into chest drainage, thoracic duct ligation, pleurodesis, pleurectomy, and others.
On the basis of end-user, the global vanishing bone disease market is segmented as hospitals & clinics, diagnostic centers, ambulatory surgical centers, and others. Geographically, the global vanishing bone disease market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American vanishing bone disease market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.
The European vanishing bone disease market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the rest of Western Europe.
The Asia Pacific, vanishing bone disease market, is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia Pacific. The Middle Eastern and African vanishing bone disease market is segmented into the Middle East and Africa.
Regional Global Vanishing Bone Disease Market Summary
The global vanishing bone disease market consists of four regions: Americas, Europe, Asia Pacific and the Middle East & Africa. The North American region dominates the global vanishing bone market due to the existing well-established healthcare system, increasing occurrences of rare diseases. For instance, according to the National Institute of Health, rare disorders that affect approximately 30 million people in the United States. Furthermore, according to the U.S. FDA, rare diseases or disorder affects an approximate 200,000 people in the United States.
Europe holds the second market share in the global vanishing bone disease market. It is expected that the government support towards research & development expenditure and rising incidences of rare diseases is likely to drive the European vanishing bone disease market. For instance, according to the European Commission, rare diseases comprises 5000 to 8000 life-threatening or chronically debilitating diseases which together affect from 27 and 36 million people in the European Union.
The Asia Pacific, vanishing bone disease market, consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia Pacific. The market growth in this region is driven by rising healthcare expenditure, rising occurrences of rare diseases, and growing bone disorders, technological advancements in interventional radiology segment. For instance, in February 2018, Elekta AB received clearance from China Food and Drug Administration (CFDA) for its Leksell Gamma Knife Icon radiosurgery system.
The Middle East & Africa holds the lowest share of the global vanishing bone disease market due to lack of awareness of rare diseases, the low incidence rate of the disease and poor medical facilities, especially in the African region.
Get Discount @ https://www.marketresearchfuture.com/check-discount/6147
Varian Medical Systems, Inc., Elekta AB, C. R. Bard, Inc., Teleflex Incorporated, Vygon S.A. Medtronic plc., Cook Medical, Smiths Medical, ATMOS MedizinTechnik GmbH & Co. KG, Merck & Co., Sanofi-Aventis, F. Hoffmann-La Roche AG, and Novartis International AG are some prominent players in this market.
Vanishing Bone Disease Market Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Ask To Experts @ https://www.marketresearchfuture.com/enquiry/6147
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar